Latest clinical information on Zika virus available at info centers on Elsevier Connect and The Lancet

To help healthcare professionals, medical researchers and the public understand the ongoing outbreak of the Zika virus, Elsevier has created a Zika Virus Resource Center on Elsevier's public news and information website. In addition, The Lancet, one of Elsevier's top medical journals, has created a Zika virus resource centre on its website, where healthcare professionals can read the latest updates, research, reviews, editorials, correspondence and commentary on the outbreak.

Both resource centers are free to the public
"With our virus resource center on The Lancet, and with one on Elsevier Connect, we strive to bring together the best available evidence on Zika to assist researchers, policy makers and health workers in understanding the effects of the outbreak and how best to respond," said Richard Horton, Editor-in-Chief of The Lancet. "Decisions affecting the public's health should be supported by the best available evidence, and our resource center will aim to keep policy makers and others updated with the latest research and analysis as developments unfold."

Both info centers are advised by clinicians and professional editors and will be updated with the most current research and evidence-based information available. Elsevier publishes about 25 percent of the world’s scientific content, including thousands of textbooks and journals, drug information, clinical guidelines and patient education.

The Elsevier Connect information center also links to other authoritative resources, including the US Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO). In addition, the site features links to data from Scopus and SciVal, which provide insight into global Zika research trends, and Mendeley, which established a Zika Virus Reference Group to share references to relevant articles to support the research community's work in finding a vaccine.

Both The Lancet and Elsevier Connect developed similar resource centers during the Ebola epidemic.

About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions - among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey - and publishes over 2,500 journals, including The Lancet and Cell, and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc, a world-leading provider of information solutions for professional customers across industries.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...